Showing results (581-590 of 7,006) with videos related to

Sort By:
Pageof 701
Lung Cancer (Amsterdam, Netherlands)|October 1, 2018
Carving out another slice of the pie: Exceptional response to single agent imatinib in an asian female never-smoker with advanced NSCLC with a de-novo PDGFR-α N848 K mutationSamuel J Klempner, Kyle Gowen, Thomas K Lee, et al.
Lung Cancer (Amsterdam, Netherlands)|May 18, 2019
Predictive value of serum protein levels in patients with advanced non-small cell lung cancer treated with nivolumabJun Oyanagi, Yasuhiro Koh, Koichi Sato, et al.
Lung Cancer (Amsterdam, Netherlands)|May 18, 2019
Lung cancer incidence in female rises significantly in urban sprawl of Shanghai after introduction of LDCT screeningFei Liang, Chunxiao Wu, Haiyan Gu, et al.
Lung Cancer (Amsterdam, Netherlands)|May 18, 2019
Sequencing of therapy following first-line afatinib in patients with EGFR mutation-positive non-small cell lung cancerKeunchil Park, Jaafar Bennouna, Michael Boyer, et al.
Lung Cancer (Amsterdam, Netherlands)|May 18, 2019
Epidermal growth factor receptor-targeted immunomagnetic liposomes for circulating tumor cell enumeration in non-small cell lung cancer treated with epidermal growth factor receptor-tyrosine kinase inhibitorsShaohua Cui, Yiqian Ni, Yizhuo Zhao, et al.
Lung Cancer (Amsterdam, Netherlands)|May 18, 2019
Association of TP53 mutations with response and longer survival under immune checkpoint inhibitors in advanced non-small-cell lung cancerSandra Assoun, Nathalie Theou-Anton, Marina Nguenang, et al.
Lung Cancer (Amsterdam, Netherlands)|March 11, 2022
Osimertinib-induced syndrome of inappropriate secretion of antidiuretic hormone in oncogene-addicted lung adenocarcinoma: A case reportMarcus Skribek, Benedek Bozoky, Georgios Tsakonas
Lung Cancer (Amsterdam, Netherlands)|March 18, 2022
Disparate genomic characteristics of patients with early-stage lung adenocarcinoma manifesting as radiological subsolid or solid lesionsHao Li, Zewen Sun, Yanmeng Li, et al.
Lung Cancer (Amsterdam, Netherlands)|April 4, 2022
Geographic distribution of malignant mesothelioma incidence and survival in AustraliaJessica K Cameron, Joanne Aitken, Alison Reid, et al.
Lung Cancer (Amsterdam, Netherlands)|March 4, 2022
Characterizing immune-mediated adverse events with durvalumab in patients with unresectable stage III NSCLC: A post-hoc analysis of the PACIFIC trialJarushka Naidoo, Johan F Vansteenkiste, Corinne Faivre-Finn, et al.
Pageof 701